| KALA BIO Announces Chief Executive Officer Transition |
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. |
globenewswire.com |
2025-02-12 10:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO Announces $10,750,000 Private Placement |
ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series I Convertible Non-Redeemable Preferred Stock (the “Series I Preferred Stock”), for aggregate gross proceeds of approximately $10.75 million, before deducting offering expenses. |
globenewswire.com |
2024-12-30 10:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? |
KALA BIO (KALA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2024-12-16 12:57:23 |
Czytaj oryginał (ang.) |
| KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference |
ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY on Wednesday, December 4, 2024 at 11:30 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, December 4, 2024. |
globenewswire.com |
2024-11-27 10:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade |
KALA BIO (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-09 17:05:24 |
Czytaj oryginał (ang.) |
| KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now |
KALA BIO (KALA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2024-08-23 14:55:40 |
Czytaj oryginał (ang.) |
| KALA BIO to Present at Jefferies Global Healthcare Conference |
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 5, 2024. |
globenewswire.com |
2024-05-29 12:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update |
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases -- |
globenewswire.com |
2024-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect? |
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-04-04 14:56:07 |
Czytaj oryginał (ang.) |
| KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update |
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opportunities to expand KPI-012 into additional corneal indications -- -- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. |
globenewswire.com |
2024-03-29 10:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference |
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also be available for one-on-one meetings on Monday, March 4, 2024. |
globenewswire.com |
2024-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-01-19 18:01:00 |
Czytaj oryginał (ang.) |
| KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates |
KALA BIO (KALA) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $19.25 per share a year ago. |
zacks.com |
2023-11-13 12:32:40 |
Czytaj oryginał (ang.) |
| KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update |
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM award, expected to fund operations into 2Q 2025 -- ARLINGTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. |
globenewswire.com |
2023-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2023-09-20 20:01:00 |
Czytaj oryginał (ang.) |
| KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference |
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded presentation will be made available beginning on Monday, September 11, 2023 at 7:00 a.m. ET. Management will also be available for one-on-one meetings throughout the conference. |
globenewswire.com |
2023-09-05 12:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update |
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarded $15 million grant by California Institute for Regenerative Medicine (CIRM) to support ongoing KPI-012 program for the treatment of PCED -- -- Rebranded to KALA BIO, Inc. reflecting focus on advancing biologics for the treatment of rare, serious ophthalmic diseases -- -- As of June 30, 2023, $59.2 million in cash, cash equivalents and short-term investments; together with $15.0 million CIRM award expected to fund operations into 2Q 2025 -- ARLINGTON, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. |
globenewswire.com |
2023-08-04 12:00:00 |
Czytaj oryginał (ang.) |
| KALA BIO to Participate in Upcoming Investor Conferences in August |
ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will participate in the following investor conferences in August 2023: |
globenewswire.com |
2023-08-02 20:01:00 |
Czytaj oryginał (ang.) |
| Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2023-07-19 20:01:00 |
Czytaj oryginał (ang.) |
| Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference |
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference being held in New York, NY. Members of Kala's management team will participate in a fireside chat on Friday, June 9, 2023 at 11:55 a.m. ET. Management will also be available for one-on-one meetings on Friday, June 9, 2023. |
globenewswire.com |
2023-06-02 12:00:00 |
Czytaj oryginał (ang.) |
| Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update |
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 -- -- Received FDA Fast Track designation for KPI-012 for the treatment of PCED -- -- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. |
globenewswire.com |
2023-05-09 12:00:00 |
Czytaj oryginał (ang.) |